Artificial intellgence analyses biomarker changes in neovascular AMD treated with faricimab
The phase 3 LUCERNE and TENAYA trials suggested that faricimab may allow clinicians to extend the interval between injections to up to 16 weeks after an initial loading phase
Clinicians may improve follow-up adherence by leveraging social media apps
Social media smartphone application–based interventions significantly improved adherence and parental knowledge among families of children with congenital ectopia lentis
Journal of Neuroinflammation publishes data on Eleva’s lead retinal asset CPV-104
In an established animal model of age-related macular degeneration, Eleva’s recombinant human CPV-104 improved two hallmarks of the disease
Alcon marks 110th anniversary of Grieshaber AG site in Switzerland
Alcon acquired the historic ophthalmic instrument company in 2000
Eyestem Research announces positive results from phase 1 geographic atrophy trial
Bangalore-based Eyestem will share more research findings on Eyecyte-RPE at this year's Association for Research in Vision and Ophthalmology meeting
When will gene therapy be ready for patients with age-related macular degeneration?
Antibody drug discovery company Novelty Nobility joins Johnson & Johnson JLABS Korea
The company's therapeutic candidates include a bispecific antibody to target vascular retinal diseases
"Reel vision syndrome" and short-form videos linked to negative ocular health outcomes
Ophthalmologists report that dry eye syndrome, myopia progression and other ocular pathologies have increased, especially among paediatric patient groups
UK surgeon performs 30,000th laser eye procedure
A pioneer of refractive laser eye surgery in the UK, Professor David Gartry, MD, FRCS, FRCOphth, FCOptom, reached the milestone in the 36th year of his career
Bayer submits EMA application for aflibercept 8mg third indication, retinal vein occlusion
In the European Union and the United Kingdom, aflibercept 8mg (Eylea HD in the US) is currently approved for neovascular age-related macular degeneration and diabetic macular oedema
Rethinking race as a risk factor for glaucoma
Social determinants of health challenge our existing expectations
European Commission expands upadacitinib (Rinvoq) indication to include giant cell arteritis
Patients with GCA, an autoimmune disease, are at risk for sudden vision loss which can be permanent
Tenpoint Therapeutics submits US FDA New Drug Application for presbyopia treatment BRIMOCHOL PF
Following Phase 3 pivotal trial BRIO-II, Tenpoint Therapeutics said they hope to launch BRIMOCHOL PF in 2026
Paediatric patients with early-onset atopic dermatitis show higher uveitis risk
The study findings support the need to consider ophthalmologic monitoring in children with early-onset atopic dermatitis
Canalicular gel Lacrifill (Nordic Pharma) receives CE Mark
Nordic Pharma plans to announce commercialisation details in the near future for the dry eye disease treatment
A real-world study of an AI system for enhanced detection of diabetic retinopathy
Fundus images of diabetic retinopathy were assessed by general ophthalmologists, retina specialists and the Aireen artificial intelligence system
A panel discussion on extended treatment intervals in retinal therapy breaks the mold at COPHy 2025
Treatment regimens with long-duration therapies continue to be a conversation starter among retina specialists
How embracing opposition sends clinicians home from COPHy with more useful takeaways
The Congress on Controversies in Ophthalmology highlights debates, but also discussions
Surgical, medical and next-generation retina topics at COPHy
Retina topics serve as the backbone of the scientific programme at this year’s Congress on Controversies in Ophthalmology
Retina recap: EMA and US FDA approvals, March 2025
Regulatory agencies issued approvals for new treatments and expanded uses of existing therapies in the retina space
US FDA issues second Complete Response Letter for dry eye drug reproxalap (Aldeyra Therapeutics)
Aldeyra previously received a CRL for its initial New Drug Application for reproxalap in November 2023
Opthea discontinues COAST and ShORe sozinibercept combination therapy trials
Both trials failed to meet their primary endpoints for treatment of age-related macular degeneration
French OPHTAMYOP study reveals trends in myopia control
How studies into myopia management can increase access to vision care
EMA grants positive CHMP opinion for low-dose atropine SYD-101 (Ryjunea, Sydnexis)
A pivotal phase 3 clinical trial found that SYD-101 met its 3-year primary endpoint for slowing paediatric myopia progression
New study investigates ocular involvement in multiple myeloma
Hematologists and ophthalmologists could work together for earlier diagnoses, research findings indicate
Up for debate: Clinicians take on hot topics at the Congress on Controversies in Ophthalmology
This year, the COPHy meeting moves beyond retina, addressing uveitis, neuro-ophthalmology and glaucoma in Seville, Spain
International study illuminates economic burden of late-stage age-related macular degeneration
Researchers assessed the costs to patients and caregivers in Germany, Bulgaria and the US
Accommodative intraocular lenses: Are they coming back?
A resurgence in this IOL technology could create new possibilities in refractive correction
Paediatric myopia study indicates lens thickness and power changes closely associated with age
The study assessed a large paediatric cohort for changes in spherical equivalent refraction, axial length, lens power and lens thickness
Alcon acquires majority interest in cell therapy company Aurion Biotech, provides operational updates
AURN001 is Aurion Biotech's clinical-stage allogeneic cell therapy asset for corneal oedema secondary to corneal endothelial disease
